Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine
Executive Summary
Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.
You may also be interested in...
Sobi Exits Nirsevimab Cost-Sharing Pact With AstraZeneca, Simplifies Royalty Deal With Sanofi
Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.
AstraZeneca And Sanofi March Ahead With Positive Phase III RSV Data
AstraZeneca and Sanofi have leapt forward in their plans to shake up the RSV market with earlier than expected positive data for their passive immunization product nirsevimab. Rival maternal vaccines in development will cast a shadow, however.
Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
The latest drug development news and highlights from our US FDA Performance Tracker.